Skip to content

Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01297400
Enrollment
60
Registered
2011-02-16
Start date
2022-03-11
Completion date
2026-12-31
Last updated
2026-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Burns

Keywords

Burns, Partial Thickness Burns

Brief summary

To compare MW-III to Silvadene® Cream 1% (Silver Sulfadiazine) with respect to "time to healing" (≥95% re-epithelialization) of a partial thickness target thermal burn.

Detailed description

This phase 2 pilot study will assess the safety and efficacy of topical MW-III on thermal burns.

Interventions

DRUGInvestigational Drug, MW-III

Topical application, twice a day

DRUGSilvadene® Cream 1% [Silver Sulfadiazine]

Topical application, twice a day

Sponsors

Skingenix, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Adults, 18 years of age or older on the day of signing the informed consent. 2. Thermal Burns not exceeding a total body surface area (TBSA) OF 25%, with at least one partial thickness burn of 0.5% TBSA or greater. If full thickness burn(s) are present at screening, the total full thickness burn area shall not exceed 10% TBSA. Note: TBSA excludes areas of superficial (first degree) burns. 3. Able and willing to give informed consent and comply with study procedures.

Exclusion criteria

1. Any burn that at screening is: 1. infected. 2. circumferential or deemed, in the judgment of the investigator, at high risk for developing compartment syndrome. 3. partial thickness that is likely, in the judgment of the Investigator, to require grafting within 72 hours, or other non-protocol intervention. 2. Severe inhalation injury or other significant non-burn trauma.

Design outcomes

Primary

MeasureTime frameDescription
Time to healing (≥95% re-epithelialization) of the partial thickness target burn.28 days Treatment PeriodTime to healing (≥95% re-epithelialization) of the partial thickness target burn.

Secondary

MeasureTime frameDescription
Scar scores (POSAS) of the partial thickness target burn and all other partial thickness burns at Day 28.28 days Treatment PeriodScar scores (POSAS) of the partial thickness target burn and all other partial thickness burns at Day 28.
Proportion of subjects with partial thickness burns that are healed at each scheduled study assessment.28 days Treatment PeriodProportion of subjects with partial thickness burns that are healed at each scheduled study assessment.
Proportion of subjects with partial thickness burns determined by PI to require skin grafting of burn wound by Day 28.28 days Treatment PeriodProportion of subjects with partial thickness burns determined by PI to require skin grafting of burn wound by Day 28.

Countries

Mexico, United States

Contacts

CONTACTVicki Christodoulou, MS, JD
vickic@skingenixusa.com909-587-1650
CONTACTEric Wang, MD
ericw@skingenixusa.com909-587-1650
PRINCIPAL_INVESTIGATORKevin Foster

Valleywise Health Medical Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 17, 2026